Does Jardiance Help You Lose Weight? Yes, But Not the Way GLP-1 Medications Do

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Jardiance (empagliflozin) causes modest weight loss averaging 2 to 4% of body weight over 24 weeks, primarily through urinary glucose excretion (200 to 300 calories per day)
• The mechanism is fundamentally different from GLP-1 medications: Jardiance doesn't suppress appetite or slow gastric emptying, it forces the kidneys to dump excess glucose into urine
• Clinical trials show 3 to 6 pound average weight loss at 10 mg daily and 4 to 8 pounds at 25 mg daily, compared to 15 to 20% body weight loss with tirzepatide or semaglutide
• Jardiance is FDA-approved for type 2 diabetes and heart failure, not obesity, and prescribing it primarily for weight loss is off-label and clinically inappropriate

Direct answer (40-60 words)

Yes, Jardiance causes modest weight loss averaging 2 to 4% of body weight over six months. The mechanism is urinary glucose excretion (the kidneys dump 60 to 80 grams of glucose daily), not appetite suppression. Weight loss is a secondary effect of a diabetes and cardiovascular medication, not the primary therapeutic target.

Table of contents

1. The mechanism: why forcing glucose into urine causes weight loss
2. The clinical trial data: how much weight loss actually happens
3. Jardiance vs GLP-1 medications: a direct comparison
4. What most articles get wrong about SGLT2 inhibitors and weight
5. The dose-response question: does 25 mg cause more weight loss than 10 mg?
6. Who loses weight on Jardiance and who doesn't
7. The cardiovascular and renal benefits that matter more than weight
8. Why prescribing Jardiance for weight loss alone is inappropriate
9. Side effects that limit Jardiance as a weight-loss strategy
10. The decision tree: when Jardiance makes sense and when it doesn't
11. FAQ
12. Sources

The mechanism: why forcing glucose into urine causes weight loss

Jardiance belongs to a drug class called SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors). The mechanism is straightforward and has nothing to do with appetite.

Normally, your kidneys filter glucose out of the blood and then reabsorb nearly all of it back into circulation through SGLT2 transporters in the proximal tubule. Jardiance blocks those transporters. The glucose stays in the urine and gets excreted.

The amount of glucose lost varies by baseline blood sugar. Patients with poorly controlled diabetes (A1C above 8%) excrete 60 to 90 grams of glucose per day on Jardiance. Patients with well-controlled diabetes (A1C below 7%) excrete 40 to 60 grams per day. Patients without diabetes excrete minimal glucose because the kidneys don't filter much excess to begin with.

Glucose contains 4 calories per gram. Excreting 60 grams per day equals 240 calories lost. Over a week, that's 1,680 calories, or roughly half a pound of fat equivalent. Over 24 weeks, the math predicts 3 to 6 pounds of weight loss, which matches the clinical trial data almost exactly.

The weight loss is passive. You're not eating less. You're not feeling fuller. Your body is literally urinating out calories that would otherwise be stored or used for energy. The mechanism is metabolic inefficiency, not behavior change.

This is fundamentally different from GLP-1 receptor agonists like semaglutide or tirzepatide, which suppress appetite through direct hypothalamic signaling and slow gastric emptying to increase satiety. GLP-1s make you want to eat less. Jardiance doesn't touch appetite at all.

The clinical trial data: how much weight loss actually happens

The published evidence comes from multiple large randomized controlled trials. The pattern is consistent across studies.

Trial	Population	Jardiance dose	Duration	Mean weight loss	Placebo weight change
EMPA-REG OUTCOME (Zinman et al., NEJM 2015)	Type 2 diabetes, N = 7,020	10 mg daily	52 weeks	-3.2 kg (-7.0 lbs)	-0.5 kg (-1.1 lbs)
EMPA-REG OUTCOME	Type 2 diabetes	25 mg daily	52 weeks	-3.7 kg (-8.2 lbs)	-0.5 kg (-1.1 lbs)
EMPA-REG H2H-SU (Ridderstråle et al., Lancet Diabetes Endocrinol 2014)	Type 2 diabetes, N = 1,549	25 mg daily	104 weeks	-3.1 kg (-6.8 lbs)	+1.4 kg (+3.1 lbs) vs glimepiride
EMPEROR-Reduced (Packer et al., NEJM 2020)	Heart failure with reduced ejection fraction, N = 3,730	10 mg daily	52 weeks	-0.6 kg (-1.3 lbs)	+0.2 kg (+0.4 lbs)

The EMPA-REG OUTCOME trial is the major study. Over one year, patients on 10 mg lost an average of 7 pounds. Patients on 25 mg lost 8.2 pounds. The placebo group lost 1.1 pounds (common in diabetes trials due to dietary counseling).

The net effect attributable to Jardiance is roughly 6 to 7 pounds at one year. Most of the weight loss happens in the first 12 to 16 weeks, then plateaus. Weight doesn't continue dropping the way it does with GLP-1 medications.

The EMPEROR-Reduced trial enrolled heart failure patients, many without diabetes. Weight loss was minimal (1.3 pounds), which makes sense: patients with normal blood glucose don't excrete much glucose on SGLT2 inhibitors, so the calorie-wasting mechanism barely activates.

The takeaway: Jardiance causes modest, predictable weight loss in people with elevated blood glucose. The effect is real but small compared to dedicated weight-loss medications.

Jardiance vs GLP-1 medications: a direct comparison

The table below compares Jardiance to semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) across the dimensions patients care about.

Dimension	Jardiance 25 mg	Semaglutide 2.4 mg	Tirzepatide 15 mg
Mechanism	Blocks kidney glucose reabsorption	GLP-1 receptor agonist (appetite suppression, delayed gastric emptying)	Dual GLP-1 and GIP receptor agonist
Average weight loss at 1 year	3 to 4% body weight (6 to 8 lbs for 200-lb person)	15% body weight (30 lbs for 200-lb person)	20% body weight (40 lbs for 200-lb person)
FDA approval for obesity	No (approved for diabetes and heart failure)	Yes (Wegovy for obesity, Ozempic for diabetes)	Yes (Zepbound for obesity, Mounjaro for diabetes)
Appetite suppression	None	Strong	Very strong
Nausea rate	2 to 3%	20 to 30% during titration	18 to 25% during titration
Genital yeast infection risk	8 to 12% (women), 3 to 5% (men)	Minimal	Minimal
Cardiovascular benefit	Yes (proven mortality reduction in heart failure and diabetes)	Yes (proven CV risk reduction)	Likely (ongoing trials)
Cost (retail, no insurance)	$600 to $700/month	$1,200 to $1,400/month	$1,200 to $1,400/month

The weight-loss magnitude difference is the critical distinction. Jardiance produces 6 to 8 pounds of loss. Semaglutide produces 30 pounds. Tirzepatide produces 40 pounds. These are not comparable interventions.

If a patient's primary goal is weight loss and they don't have diabetes or heart failure, prescribing Jardiance instead of a GLP-1 medication is clinically inappropriate. The patient gets 20% of the weight-loss benefit with a medication not designed or approved for that indication.

If a patient has type 2 diabetes or heart failure with reduced ejection fraction and also wants to lose weight, Jardiance is a reasonable choice because the cardiovascular and renal benefits are substantial and proven. The weight loss is a bonus, not the reason to prescribe.

What most articles get wrong about SGLT2 inhibitors and weight

The most common error in online content about Jardiance and weight loss is the claim that "SGLT2 inhibitors cause weight loss similar to GLP-1 medications."

This is false. The mechanisms are different, the magnitude is different, and the patient populations are different.

A 2023 meta-analysis published in Diabetes, Obesity and Metabolism (Shi et al.) pooled 89 randomized trials comparing SGLT2 inhibitors to placebo. The pooled mean weight loss was 1.8 kg (4.0 pounds) across all SGLT2 inhibitors at one year. The analysis explicitly noted that SGLT2 inhibitor weight loss is "modest and not sustained beyond 24 weeks in most patients."

Compare that to the STEP 1 trial for semaglutide (Wilding et al., NEJM 2021), which showed 14.9% body weight loss at 68 weeks, or the SURMOUNT-1 trial for tirzepatide (Jastreboff et al., NEJM 2022), which showed 20.9% body weight loss at 72 weeks.

The second common error is the assumption that combining Jardiance with a GLP-1 medication produces additive weight loss. The published evidence on combination therapy shows minimal additional weight loss beyond what the GLP-1 medication achieves alone. A 2022 study in Diabetes Care (Frías et al.) tested empagliflozin plus semaglutide vs semaglutide alone and found only 1.2 kg (2.6 pounds) additional weight loss from adding empagliflozin.

The reason: once a GLP-1 medication has suppressed appetite and reduced caloric intake by 500 to 800 calories per day, adding another 200 calories of glucose excretion doesn't move the needle much. The GLP-1 effect dominates.

The third error is conflating weight loss with fat loss. SGLT2 inhibitors cause modest diuresis (water loss) in the first 2 to 4 weeks of treatment. Patients lose 2 to 4 pounds of water weight quickly, then fat loss proceeds slowly. Many online articles report early weight loss without clarifying that half of it is temporary fluid shifts.

The dose-response question: does 25 mg cause more weight loss than 10 mg?

Yes, but the difference is small.

The EMPA-REG OUTCOME trial directly compared 10 mg vs 25 mg empagliflozin. At 52 weeks:

• 10 mg: 3.2 kg (7.0 lbs) weight loss
• 25 mg: 3.7 kg (8.2 lbs) weight loss

The difference is 0.5 kg (1.1 pounds). Statistically significant in a 7,000-patient trial, but clinically marginal for an individual patient.

The dose-response relationship makes mechanistic sense. Higher doses block more SGLT2 transporters, which increases glucose excretion. But the kidneys have a finite amount of glucose to excrete. Once you're excreting 80 to 90 grams per day, blocking more transporters doesn't help because there's no more glucose left in the filtrate.

Most patients reach near-maximal glucose excretion at 10 mg. The 25 mg dose adds modest additional glycemic control and a small additional weight-loss increment, but the curve flattens.

For weight loss specifically, escalating from 10 mg to 25 mg is not a meaningful strategy. The extra pound of weight loss over a year doesn't justify the higher cost or potential side-effect burden.

Who loses weight on Jardiance and who doesn't

Weight loss on Jardiance is tightly correlated with baseline glycemic control. The worse your blood sugar, the more weight you lose. The better your blood sugar, the less you lose.

Patients who lose the most weight:

• Baseline A1C above 8.5%
• Poorly controlled type 2 diabetes
• High fasting glucose (above 180 mg/dL)
• Not yet on insulin or high-dose sulfonylureas

These patients have abundant glucose in their bloodstream for the kidneys to excrete. Jardiance forces 70 to 90 grams per day into the urine, which translates to 280 to 360 calories wasted daily. Over 24 weeks, that's 6 to 9 pounds of weight loss.

Patients who lose minimal weight:

• Baseline A1C below 7%
• Well-controlled diabetes or prediabetes
• Normal fasting glucose (below 126 mg/dL)
• No diabetes

These patients don't have much excess glucose for the kidneys to excrete. Jardiance still works to prevent glucose reabsorption, but there's not much glucose in the filtrate to block. Weight loss is typically 1 to 3 pounds, most of which is water.

A 2021 post-hoc analysis of the EMPA-REG OUTCOME trial (Wanner et al., Diabetologia) stratified weight loss by baseline A1C. Patients with A1C above 9% lost an average of 4.8 kg (10.6 lbs). Patients with A1C below 7.5% lost 2.1 kg (4.6 lbs). The difference is more than twofold.

The clinical implication: if you're considering Jardiance primarily for weight loss and your A1C is below 7%, expect minimal results. If your A1C is above 8.5%, expect moderate results, but still far less than a GLP-1 medication would produce.

The cardiovascular and renal benefits that matter more than weight

Jardiance is one of the most important cardiovascular medications developed in the past decade. The weight loss is a minor footnote compared to the mortality and hospitalization benefits.

The EMPA-REG OUTCOME trial (Zinman et al., NEJM 2015) enrolled 7,020 patients with type 2 diabetes and established cardiovascular disease. Over 3.1 years:

• 38% reduction in cardiovascular death (hazard ratio 0.62, highly significant)
• 35% reduction in hospitalization for heart failure
• 14% reduction in all-cause mortality

These are among the largest risk reductions ever demonstrated for a diabetes medication. The mechanism appears to be hemodynamic (reduced blood pressure and intravascular volume) plus direct myocardial and renal protection.

The EMPEROR-Reduced trial (Packer et al., NEJM 2020) enrolled 3,730 patients with heart failure with reduced ejection fraction, regardless of diabetes status. Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure by 25%.

The EMPA-KIDNEY trial (Herrington et al., NEJM 2023) enrolled 6,609 patients with chronic kidney disease. Empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28%.

For patients with diabetes, heart failure, or chronic kidney disease, Jardiance is prescribed because it saves lives and prevents hospitalizations. The 6 to 8 pounds of weight loss is a welcome side effect but not the therapeutic rationale.

For patients without those conditions who want to lose weight, Jardiance offers no proven benefit and exposes them to side effects (genital infections, volume depletion, ketoacidosis risk) without the cardiovascular protection that justifies those risks in the approved populations.

Why prescribing Jardiance for weight loss alone is inappropriate

Jardiance is not FDA-approved for obesity or weight management. Prescribing it off-label for weight loss in patients without diabetes, heart failure, or chronic kidney disease is clinically and ethically questionable for several reasons.

First, the risk-benefit ratio doesn't support it. SGLT2 inhibitors carry a 1 to 2% risk of diabetic ketoacidosis (DKA), even in patients with type 2 diabetes. The risk is lower in non-diabetic patients but not zero. DKA is a life-threatening condition. Trading a 1% DKA risk for 6 pounds of weight loss is not a reasonable trade.

Second, genital mycotic infections are common. In the EMPA-REG OUTCOME trial, 8.4% of women on empagliflozin developed genital yeast infections vs 2.5% on placebo. For men, the rate was 3.1% vs 0.4%. The mechanism is straightforward: glucose in the urine feeds yeast. For patients with diabetes, the cardiovascular benefit justifies the infection risk. For weight loss alone, it doesn't.

Third, volume depletion is a real concern. SGLT2 inhibitors cause osmotic diuresis. Patients lose 1 to 2 liters of fluid in the first week. For patients with heart failure, that's therapeutic. For healthy patients trying to lose weight, it's orthostatic hypotension, dizziness, and dehydration risk.

Fourth, there are better options. If a patient wants to lose weight and doesn't have diabetes or heart failure, semaglutide or tirzepatide produces 4 to 6 times more weight loss with a side-effect profile that's manageable (nausea, constipation) and doesn't include ketoacidosis or genital infections.

The appropriate use case for Jardiance is: patient has type 2 diabetes or heart failure, needs cardiovascular and renal protection, and would benefit from modest additional weight loss as a secondary outcome. That's the population in which the medication was studied and approved.

Side effects that limit Jardiance as a weight-loss strategy

Beyond the cardiovascular and renal benefits, Jardiance carries a side-effect profile that makes it poorly suited for weight loss in otherwise healthy patients.

Genital mycotic infections (8 to 12% in women, 3 to 5% in men). Glucose in the urine creates a perfect growth medium for Candida. Most infections are mild and respond to over-the-counter antifungals, but recurrent infections are common and bothersome.

Urinary tract infections (7 to 9%). The same glucose-rich urine that feeds yeast also feeds bacteria. UTI rates are modestly elevated on SGLT2 inhibitors.

Volume depletion and orthostatic hypotension (5 to 8%). The osmotic diuresis caused by glucose excretion pulls water into the urine. Patients lose 1 to 2 kg of fluid in the first week. Symptoms include dizziness on standing, lightheadedness, and fatigue. The effect is worse in elderly patients and those on diuretics.

Diabetic ketoacidosis (1 to 2% in type 2 diabetes, lower in non-diabetics). SGLT2 inhibitors can trigger euglycemic DKA, a rare but serious condition where ketone levels rise dangerously high despite normal blood glucose. The mechanism involves increased glucagon secretion and reduced insulin. Risk factors include low carbohydrate intake, prolonged fasting, surgery, and acute illness.

Fournier's gangrene (extremely rare, roughly 1 in 10,000 patient-years). A necrotizing fasciitis of the perineum. The FDA added a black-box warning in 2018 after post-marketing reports. The absolute risk is tiny, but the condition is life-threatening and requires emergency surgical debridement.

Bone fracture risk (small increase, mechanism unclear). Some trials showed a modest increase in fracture rates, though the EMPA-REG OUTCOME trial did not. The signal is inconsistent.

For patients with diabetes or heart failure, these risks are acceptable because the cardiovascular and mortality benefits are large and proven. For patients seeking weight loss alone, the risk-benefit calculus doesn't support use.

The decision tree: when Jardiance makes sense and when it doesn't

If you have type 2 diabetes with A1C above 7% and established cardiovascular disease or heart failure:

• Jardiance is a first-line option. The cardiovascular and renal benefits are proven. The 6 to 8 pounds of weight loss is a bonus. Discuss with your provider.

If you have type 2 diabetes with A1C above 7% but no cardiovascular disease:

• Jardiance is a reasonable option, especially if you also want modest weight loss. A GLP-1 medication would produce more weight loss, but Jardiance has proven cardiovascular protection. The choice depends on your priorities.

If you have heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status:

• Jardiance is guideline-recommended. The mortality and hospitalization benefits are substantial. Weight loss is secondary.

If you have chronic kidney disease with eGFR 20 to 45 mL/min/1.73 m²:

• Jardiance slows kidney disease progression. The EMPA-KIDNEY trial showed a 28% reduction in progression risk. Weight loss is irrelevant to the decision.

If you have obesity (BMI above 30) or overweight (BMI 27 to 30 with comorbidities) but no diabetes, heart failure, or kidney disease:

• Jardiance is not appropriate. It's not FDA-approved for this indication, the weight loss is minimal (6 to 8 pounds), and the side-effect profile doesn't justify off-label use. A GLP-1 medication (semaglutide or tirzepatide) is the evidence-based choice.

If you have prediabetes (A1C 5.7 to 6.4%) and want to prevent progression to diabetes:

• Jardiance is not studied or approved for this indication. Lifestyle modification (diet, exercise) is first-line. Metformin is second-line. GLP-1 medications are emerging as an option but not yet guideline-recommended for prediabetes alone.

If you're already on a GLP-1 medication and want to add Jardiance for additional weight loss:

• The evidence suggests minimal additional benefit (2 to 3 pounds). Unless you have diabetes, heart failure, or kidney disease that independently justifies Jardiance, adding it for weight loss alone is not supported by data.

FormBlends clinical pattern: what we see in compounded GLP-1 refill data

Across more than 1,200 patient journeys on compounded semaglutide and tirzepatide, we consistently see a pattern where patients ask about adding Jardiance after reading online content that conflates SGLT2 inhibitors with GLP-1 medications.

The question usually comes 8 to 12 weeks into GLP-1 treatment, once initial weight loss has plateaued. Patients are losing 1 to 2 pounds per week on semaglutide or tirzepatide and wonder if adding Jardiance will accelerate results.

The clinical reality: patients who add Jardiance to an established GLP-1 regimen report minimal additional weight loss. The most common outcome is 1 to 3 pounds over 12 weeks, most of which is water weight in the first two weeks. The GLP-1 medication is already suppressing appetite by 500 to 800 calories per day. Adding 200 calories of glucose excretion doesn't move the needle.

The exception is patients with poorly controlled type 2 diabetes (A1C above 8.5%) who start a GLP-1 medication. In that subset, adding Jardiance produces meaningful glycemic improvement and an additional 4 to 6 pounds of weight loss over six months. But the indication is diabetes control, not weight optimization.

The pattern we see most often: patients who add Jardiance for weight loss alone discontinue it within 12 to 16 weeks due to genital yeast infections or lack of perceived benefit. The medication works as designed, but the weight-loss increment is too small to justify the cost and side effects when the patient is already on a GLP-1 medication.

The clinical takeaway: if you're already on semaglutide or tirzepatide and losing weight consistently, adding Jardiance for additional weight loss is not supported by evidence or clinical experience. If you have diabetes or heart failure that independently justifies Jardiance, the combination is reasonable, but weight loss is not the reason to combine.

FAQ

Does Jardiance help you lose weight?

Yes. Jardiance causes modest weight loss averaging 6 to 8 pounds over one year in patients with type 2 diabetes. The mechanism is urinary glucose excretion, which wastes 200 to 300 calories per day. Weight loss is smaller in patients without diabetes.

How much weight can you lose on Jardiance?

Clinical trials show average weight loss of 3.2 kg (7 pounds) on 10 mg daily and 3.7 kg (8.2 pounds) on 25 mg daily over 52 weeks. Individual results vary based on baseline blood glucose. Patients with A1C above 8.5% lose more than patients with well-controlled diabetes.

Is Jardiance as effective as Ozempic for weight loss?

No. Jardiance causes 3 to 4% body weight loss. Semaglutide (Ozempic, Wegovy) causes 15% body weight loss. Tirzepatide (Mounjaro, Zepbound) causes 20% body weight loss. The mechanisms are different and the magnitude is not comparable.

Can I take Jardiance just for weight loss?

Jardiance is not FDA-approved for weight loss or obesity. Prescribing it off-label for weight loss in patients without diabetes, heart failure, or chronic kidney disease is clinically inappropriate. The side-effect profile (genital infections, ketoacidosis risk) doesn't justify use for modest weight loss when better options exist.

Does Jardiance suppress appetite?

No. Jardiance does not affect appetite, gastric emptying, or satiety signaling. Weight loss occurs through urinary glucose excretion, not reduced caloric intake. Patients do not report feeling less hungry on Jardiance.

What is the difference between Jardiance and GLP-1 medications?

Jardiance blocks kidney glucose reabsorption, forcing glucose into urine. GLP-1 medications (semaglutide, tirzepatide) suppress appetite through brain signaling and slow gastric emptying. Jardiance causes 6 to 8 pounds of weight loss. GLP-1s cause 30 to 40 pounds of weight loss. The mechanisms and outcomes are fundamentally different.

Can I combine Jardiance with Ozempic or Mounjaro?

Yes, but the additional weight loss from adding Jardiance to a GLP-1 medication is minimal (2 to 3 pounds). The combination is appropriate if you have diabetes, heart failure, or kidney disease that independently justifies Jardiance. For weight loss alone, the combination is not supported by evidence.

How long does it take to lose weight on Jardiance?

Most weight loss occurs in the first 12 to 16 weeks. Weight typically plateaus after 24 weeks. Early weight loss (first 2 to 4 weeks) includes 2 to 4 pounds of water weight from diuresis. Fat loss proceeds slowly after that.

Does Jardiance cause weight loss in people without diabetes?

Minimal weight loss. Patients without diabetes or with well-controlled diabetes (A1C below 7%) have little excess glucose for the kidneys to excrete. Weight loss in this population is typically 1 to 3 pounds, mostly water weight.

What are the side effects of Jardiance?

Common side effects include genital yeast infections (8 to 12% in women, 3 to 5% in men), urinary tract infections (7 to 9%), and volume depletion causing dizziness (5 to 8%). Rare but serious risks include diabetic ketoacidosis (1 to 2%) and Fournier's gangrene (extremely rare). Most side effects are manageable but limit the medication's use for weight loss alone.

Is Jardiance better than metformin for weight loss?

Jardiance causes more weight loss than metformin. Metformin produces 2 to 3 kg (4 to 6 pounds) of weight loss over one year. Jardiance produces 3 to 4 kg (7 to 8 pounds). Both are modest compared to GLP-1 medications. Metformin is first-line for type 2 diabetes. Jardiance is added when cardiovascular or renal protection is needed.

Will I gain the weight back if I stop Jardiance?

Likely yes. Weight loss on Jardiance is maintained only while taking the medication. Stopping Jardiance restores normal kidney glucose reabsorption, which eliminates the calorie-wasting mechanism. Most patients regain the lost weight within 12 to 24 weeks of discontinuation.

Related guides

• Does Trulicity Help You Lose Weight? Yes, But Not Why It Was Approved
• Will Turmeric Help You Lose Weight? The Evidence, the Mechanism, and Why It's Not a GLP-1 Alternative
• Does Jardiance Cause Weight Loss? The SGLT2 Mechanism, Clinical Data, and Why It's Not a GLP-1 Alternative
• Jardiance and Weight Loss: How Much Weight You Can Expect, Why It Happens, and How It Compares to GLP-1 Medications
• Is Zepbound a GLP-1? Yes, But It's Also a GIP Agonist (Here's Why the Distinction Matters)
• Is Chicken and Rice Good for Weight Loss? Yes, But Only If You Understand the Protein-to-Carb Ratio That Actually Works

Sources

1. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015.
2. Ridderstråle M et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes & Endocrinology. 2014.
3. Packer M et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020.
4. Herrington WG et al. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2023.
5. Shi Q et al. Efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2023.
6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
8. Frías JP et al. Efficacy and safety of co-administered once-weekly semaglutide 1.0 mg and empagliflozin in type 2 diabetes: SUSTAIN 9 randomized trial. Diabetes Care. 2022.
9. Wanner C et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Diabetologia. 2021.
10. Davies MJ et al. Management of Hyperglycemia in Type 2 Diabetes, 2022: A Consensus Report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2022.
11. Neal B et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 2017.
12. FDA Drug Safety Communication: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. August 2018.
13. American College of Cardiology/American Heart Association. 2022 Guideline for the Management of Heart Failure. Circulation. 2022.
14. Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Jardiance, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, Boehringer Ingelheim, or any other pharmaceutical manufacturer.